Davunetide
From PeptidePlaza, the free peptide reference · Entry #1090 · Nootropic · Sources fetched 2026-09-11 · Editorial standards
Davunetide (also known as NAP peptide, NAPVSIPQ peptide, Davunetida, AL108 cpd) is a nootropic research peptide. Davunetide, also known as NAP peptide, is a tubulin stabiliser studied for its potential in neurological disorders.
Davunetide is a synthetic octapeptide that functions as a tubulin stabiliser. It is a peptide therapeutic that has been investigated for its neuroprotective properties. Research has explored its role in various neurological disorders, with studies focusing on its safety and efficacy. Davunetide has been studied for conditions such as cognitive dysfunction, schizophrenia, and progressive supranuclear palsy, reaching Phase 2 clinical trials. Literature reviews have summarized its potential applications and current understanding.
1 Mechanism of action
Tubulin stabiliser (stabiliser)
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Cognitive Dysfunction
- Schizophrenia
- Supranuclear Palsy, Progressive
3 Chemical and physical properties
| CAS number | 211439-12-2 |
|---|---|
| Molar mass | 824.9 g/mol |
| Purity (typical) | Not independently verified |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
4 Research studies (8)
- Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity
Advanced drug delivery reviews (2025) · Review - Davunetide: Peptide therapeutic in neurological disorders
Current medicinal chemistry (2014) · Review - Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease
Translational psychiatry (2024) · RCT - Integrated ribosome and proteome analyses reveal insights into sevoflurane-induced long-term social behavior and cognitive dysfunctions through ADNP inhibition in neonatal mice
Zoological research (2024) - Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases
Expert review of clinical pharmacology (2013) · Review - Microtubules (tau) as an emerging therapeutic target: NAP (davunetide)
Current pharmaceutical design (2011) · Review - Tau, ADNP, and sex
Cytoskeleton (Hoboken, N.J.) (2024) - NAP (davunetide) provides functional and structural neuroprotection
Current pharmaceutical design (2011) · Review
5 Safety and risk profile
5.1 Regulatory status
Davunetide is currently classified as Phase 2 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
6 Frequently asked questions
- What is Davunetide?
- Davunetide, also known as NAP peptide, is a synthetic octapeptide. It is classified as a tubulin stabiliser and is being investigated as a peptide therapeutic for neurological disorders.
- How does Davunetide work?
- Davunetide functions as a tubulin stabiliser. This mechanism is believed to contribute to its neuroprotective properties, which are being explored in the context of various neurological conditions.
- What is Davunetide used for?
- Davunetide is being studied for its potential use in treating cognitive dysfunction, schizophrenia, and progressive supranuclear palsy. These are the indications for which it has reached Phase 2 clinical trials.
- What is the regulatory status of Davunetide?
- Davunetide is currently in Phase 2 clinical trials. This means it is undergoing further evaluation for its efficacy and safety in human subjects for specific indications.
7 References
- Davunetide — compound summary PubChem. View source
- Davunetide — molecule record ChEMBL. View source
- Davunetide — published literature (82 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Davunetide.
Also nootropic
Ang1005, also known as paclitaxel trevatide, is a prolow-density lipoprotein receptor-related protein 1 binding agent and tubulin inhibitor.
Also nootropic
Substance P, also known as Neurokinin P, is an endogenous human peptide and a member of the tachykinin family.
Also nootropic
Vasoactive Intestinal Peptide (VIP) is a neuropeptide that activates VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2), which are G protein-coupled receptors.
Also nootropic
A nine-amino-acid neuropeptide hormone best known for childbirth and lactation, now studied extensively for social bonding, stress regulation, wound healing, and metabolic effects via intranasal delivery.
Also nootropic
A cyclic heptapeptide melanocortin receptor agonist and active metabolite of Melanotan II. Unlike peripheral vasodilators, PT-141 acts centrally via the CNS to modulate arousal and food intake pathways.
Also nootropic
A potent cyclic analog of α-MSH that activates melanocortin receptors broadly. Studied for UV-independent melanogenesis, appetite suppression, and as the parent compound of PT-141 (Bremelanotide).